ArticleEJHaem2022

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.

Francesca Fazio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.